NO20053424L - Forbedrede farmasoytiske botulinumtoksin-preparater. - Google Patents
Forbedrede farmasoytiske botulinumtoksin-preparater.Info
- Publication number
- NO20053424L NO20053424L NO20053424A NO20053424A NO20053424L NO 20053424 L NO20053424 L NO 20053424L NO 20053424 A NO20053424 A NO 20053424A NO 20053424 A NO20053424 A NO 20053424A NO 20053424 L NO20053424 L NO 20053424L
- Authority
- NO
- Norway
- Prior art keywords
- botulinum toxin
- present
- sequestration
- tissues
- disclosed compositions
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
2005-09-16 Sammendrag O. nr. E40948 Botulinumtoksin, en velkjent systemisk gift, gir gunstige terapeutiske effekter ved regional festing til nerver i det myoneurale området og eventuelt andre vev i et målområde av et spesielt vev. Oppfinnelsen tilveiebringer preparater av botulinumtoksin og et sekvestreringsmiddel som øker sekvestreringen og avleveringen av botulinumtoksin til det neurale og assosierte vev sammenlignet med tilgjengelige formuleringer av botulinumtoksiner, og gir derved en fordelaktig klinisk effekt. Sekvestreringsmidlene ifølge oppfinnelsen inkluderer proteiner, lipider og karbohydrater. Et foretrukket preparat ifølge oppfinnelsen omfatter et botulinumtoksin og et albumin. Oppfinnelsen tilveiebringer også fremgangsmåter for behandling av neuromuskulære sykdommer og smerte ved bruk av de beskrevne preparater og metoder for fremstilling av de beskrevne preparater.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43590102P | 2002-12-20 | 2002-12-20 | |
PCT/IB2003/006145 WO2004060384A2 (en) | 2002-12-20 | 2003-12-22 | Pharmaceutical botulinum toxin compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053424D0 NO20053424D0 (no) | 2005-07-14 |
NO20053424L true NO20053424L (no) | 2005-09-16 |
Family
ID=32713047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053424A NO20053424L (no) | 2002-12-20 | 2005-07-14 | Forbedrede farmasoytiske botulinumtoksin-preparater. |
Country Status (17)
Country | Link |
---|---|
US (2) | US7491403B2 (no) |
EP (1) | EP1594523B1 (no) |
JP (1) | JP2006519761A (no) |
KR (1) | KR20050094817A (no) |
CN (1) | CN100525831C (no) |
AT (1) | ATE426408T1 (no) |
AU (2) | AU2003300666A1 (no) |
BR (1) | BR0316871A (no) |
CA (1) | CA2510058C (no) |
CR (1) | CR9813A (no) |
DE (1) | DE60326887D1 (no) |
IL (1) | IL168745A0 (no) |
MX (1) | MXPA05006690A (no) |
NO (1) | NO20053424L (no) |
NZ (1) | NZ540425A (no) |
WO (1) | WO2004060384A2 (no) |
ZA (1) | ZA200504982B (no) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
CN100525831C (zh) * | 2002-12-20 | 2009-08-12 | 肉毒素研究同仁股份有限公司 | 改进的药用肉毒杆菌毒素组合物 |
EP1599220B1 (en) * | 2003-03-06 | 2013-07-17 | Botulinum Toxin Research Associates, Inc. | Selection of patients with increased responsiveness to botulinum toxin |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
ATE451117T1 (de) * | 2004-01-05 | 2009-12-15 | Botulinum Toxin Res Ass Inc | Verfahren zur verwendung von botulinustoxin zur behandlung von hypervolämischer lippendeformität (lippen-ektropion) |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7879341B2 (en) * | 2004-07-26 | 2011-02-01 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
WO2006073410A1 (en) * | 2005-01-03 | 2006-07-13 | Botulinum Toxin Research Associates, Inc. | Compositions, methods and devices for preparing less painful botulinum toxin formulations |
US7838011B2 (en) | 2005-02-14 | 2010-11-23 | Pankaj Modi | Stabilized protein compositions for topical administration and methods of making same |
US7727537B2 (en) | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
CN103315954A (zh) | 2005-07-18 | 2013-09-25 | 麻萨诸塞州洛厄尔大学 | 制备与使用纳米乳剂的组合物和方法 |
US7655243B2 (en) | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
EP1906923B1 (en) | 2005-07-22 | 2018-01-24 | The Foundry, LLC | Systems and methods for delivery of a therapeutic agent |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
AU2013202882B2 (en) * | 2005-08-01 | 2015-11-19 | Allergan, Inc | Improved botulinum toxin compositions |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
BRPI0619134B8 (pt) | 2005-12-01 | 2021-05-25 | Univ Massachusetts Lowell | nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US20080063732A1 (en) * | 2006-07-31 | 2008-03-13 | Hantash Basil M | Method of increasing the efficacy of neurotoxin |
AU2007329579A1 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Amphiphilic entity nanoparticles |
AU2007353340A1 (en) | 2006-12-01 | 2008-11-20 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
CN103961315A (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
KR100882817B1 (ko) * | 2007-07-20 | 2009-02-10 | 숙명여자대학교산학협력단 | 보툴리늄 독소를 유효성분으로 포함하는 지방세포 생착증진용 약학적 조성물 |
US9161970B2 (en) | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
CA2723806C (en) | 2008-05-09 | 2022-05-31 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
WO2010096134A1 (en) | 2008-12-04 | 2010-08-26 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
JP5688031B2 (ja) * | 2009-01-07 | 2015-03-25 | ロバート ジョン ペトレラ, | ヒアルロン酸およびボツリヌス毒素を使用する軟組織傷害の治療 |
CA2766649C (en) | 2009-06-24 | 2016-08-23 | Charles N.S. Soparkar | Zinc supplementation to increase responsiveness to metalloprotease therapy |
EP4193948A1 (en) | 2009-10-27 | 2023-06-14 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
EP4111995A1 (en) | 2009-11-11 | 2023-01-04 | Nuvaira, Inc. | Device for treating tissue and controlling stenosis |
ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
CA2867143C (en) | 2012-03-12 | 2016-03-29 | William J. Binder | Treatment of migraine headaches with presynaptic neurotoxin |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
KR20180114891A (ko) * | 2016-03-02 | 2018-10-19 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소를 포함하는 조성물 |
CA3018018A1 (en) * | 2016-03-25 | 2017-09-28 | Ipsen Biopharm Limited | Collecting physical therapy information to enhance treatment efficacy of botulinum toxin |
WO2017188618A1 (en) * | 2016-04-26 | 2017-11-02 | Korea Prime Pharm Co., Ltd. | A novel composition comprising botulinum toxin |
KR101636846B1 (ko) * | 2016-06-08 | 2016-07-07 | (주)넥스젠바이오텍 | 피부 세포 증식 및 항산화 효과가 증가한 보툴리눔 톡신-인간상피세포성장인자 융합단백질 및 이를 유효성분으로 함유하는 피부 재생 및 주름 개선용 화장료 조성물 |
ES2917248T3 (es) * | 2016-08-26 | 2022-07-07 | Sk Joint Ventures Ii Llc | Formulaciones de polímeros biodegradables para aumentar la eficacia de la toxina botulínica |
ES2755815T3 (es) | 2016-09-13 | 2020-04-23 | Allergan Inc | Composiciones de toxina de Clostridium no proteicas estabilizadas |
AU2017360346B2 (en) | 2016-11-21 | 2023-11-23 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
CN106860756A (zh) * | 2017-03-29 | 2017-06-20 | 卢仁华 | 眼睑痉挛的治疗药物 |
WO2018222652A1 (en) * | 2017-05-31 | 2018-12-06 | Allergan, Inc. | Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin |
KR20190038292A (ko) * | 2017-09-29 | 2019-04-08 | 한국프라임제약주식회사 | 효능 지속시간이 연장된 보툴리눔 독소 조성물 |
WO2020047158A1 (en) * | 2018-08-28 | 2020-03-05 | Ira Sanders | Therapeutic medications for the sphenopalatine ganglion |
KR20240032688A (ko) * | 2022-09-02 | 2024-03-12 | (주)메디톡스 | 내성 발현이 감소된 보툴리눔 독소 제제 및 이와 관련된 방법 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2160312B (en) * | 1984-04-13 | 1987-09-16 | South African Inventions | Adjuvant for immunisation |
US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US5069936A (en) | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
US5053005A (en) * | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
US5034461A (en) | 1989-06-07 | 1991-07-23 | Bausch & Lomb Incorporated | Novel prepolymers useful in biomedical devices |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
WO1994000481A1 (en) | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
JPH06192118A (ja) * | 1992-09-28 | 1994-07-12 | Wisconsin Alumni Res Found | ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法 |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
US5401452A (en) | 1993-07-26 | 1995-03-28 | Environmental Protection Polymers, Inc. | Methods for encapsulating waste and products thereof |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US6203794B1 (en) | 1994-05-31 | 2001-03-20 | Allergan Sales, Inc. | Modification of clostridial toxins for use as transport proteins |
US5583162A (en) | 1994-06-06 | 1996-12-10 | Biopore Corporation | Polymeric microbeads and method of preparation |
AU2907695A (en) | 1994-08-08 | 1996-03-07 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
DK0773788T3 (da) * | 1995-06-06 | 2003-09-01 | Allergan Inc | Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner |
AU4746096A (en) | 1995-06-06 | 1996-12-24 | Wisconsin Alumni Research Foundation | Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin |
US5939070A (en) | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
US5965699A (en) * | 1996-11-06 | 1999-10-12 | The United States Of America As Represented By The Secretary Of The Army | Assay for the proteolytic activity of serotype a from clostridium botulinum |
US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US6051239A (en) * | 1997-10-20 | 2000-04-18 | Thomas Jefferson University | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
US6214602B1 (en) * | 1998-08-28 | 2001-04-10 | Promega Corporation | Host cells for expression of clostridial toxins and proteins |
TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
AU1706400A (en) * | 1998-10-27 | 2000-05-15 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
US6545126B1 (en) * | 1999-03-18 | 2003-04-08 | Wisconsin Alumni Research Foundation | Chimeric toxins |
US7838008B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6429189B1 (en) | 1999-12-10 | 2002-08-06 | Botulinum Toxin Research Associates, Inc. | Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases |
US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
NZ520201A (en) * | 2000-02-08 | 2004-04-30 | Allergan Inc | Botulinum toxin pharmaceutical compositions comprising a polysaccharide |
US20030138460A1 (en) * | 2000-02-08 | 2003-07-24 | Allergan, Inc | Methods of treating animals with botulinum toxin pharmaceutical compositions |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
US20030086899A1 (en) * | 2000-03-14 | 2003-05-08 | Jafari Masoud R. | Chondroitin sulfate containing viscoelastics for use in treating joints |
US6579847B1 (en) * | 2000-05-01 | 2003-06-17 | Imarx Therapeutics Inc. | Method and apparatus for vascular neuromuscular blockade |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US7255865B2 (en) | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
ITUD20010002A1 (it) * | 2001-01-05 | 2002-07-05 | Univ Degli Studi Udine | Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo |
US7063860B2 (en) * | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
MXPA01011542A (es) * | 2001-11-13 | 2003-05-22 | Alcon Inc | Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel. |
US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
CN100525831C (zh) * | 2002-12-20 | 2009-08-12 | 肉毒素研究同仁股份有限公司 | 改进的药用肉毒杆菌毒素组合物 |
MXPA05009424A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento de chalazion cronico y hordeolum con la toxina botulinica. |
JP2007528352A (ja) * | 2003-03-06 | 2007-10-11 | ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド | 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療 |
ATE451117T1 (de) * | 2004-01-05 | 2009-12-15 | Botulinum Toxin Res Ass Inc | Verfahren zur verwendung von botulinustoxin zur behandlung von hypervolämischer lippendeformität (lippen-ektropion) |
WO2006073410A1 (en) * | 2005-01-03 | 2006-07-13 | Botulinum Toxin Research Associates, Inc. | Compositions, methods and devices for preparing less painful botulinum toxin formulations |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
-
2003
- 2003-12-22 CN CNB2003801067969A patent/CN100525831C/zh not_active Expired - Fee Related
- 2003-12-22 AT AT03814518T patent/ATE426408T1/de not_active IP Right Cessation
- 2003-12-22 DE DE60326887T patent/DE60326887D1/de not_active Expired - Lifetime
- 2003-12-22 AU AU2003300666A patent/AU2003300666A1/en not_active Abandoned
- 2003-12-22 EP EP03814518A patent/EP1594523B1/en not_active Revoked
- 2003-12-22 ZA ZA200504982A patent/ZA200504982B/en unknown
- 2003-12-22 WO PCT/IB2003/006145 patent/WO2004060384A2/en active Application Filing
- 2003-12-22 NZ NZ540425A patent/NZ540425A/en not_active IP Right Cessation
- 2003-12-22 JP JP2004564369A patent/JP2006519761A/ja active Pending
- 2003-12-22 CA CA2510058A patent/CA2510058C/en not_active Expired - Lifetime
- 2003-12-22 US US10/740,755 patent/US7491403B2/en not_active Expired - Lifetime
- 2003-12-22 KR KR1020057011339A patent/KR20050094817A/ko not_active Application Discontinuation
- 2003-12-22 MX MXPA05006690A patent/MXPA05006690A/es active IP Right Grant
- 2003-12-22 BR BR0316871-9A patent/BR0316871A/pt not_active Application Discontinuation
-
2005
- 2005-05-23 IL IL168745A patent/IL168745A0/en active IP Right Grant
- 2005-07-14 NO NO20053424A patent/NO20053424L/no not_active Application Discontinuation
-
2008
- 2008-03-03 US US12/073,245 patent/US8241640B2/en active Active
- 2008-03-13 CR CR9813A patent/CR9813A/es not_active Application Discontinuation
-
2010
- 2010-05-20 AU AU2010202062A patent/AU2010202062A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20053424D0 (no) | 2005-07-14 |
AU2010202062A1 (en) | 2010-06-10 |
ATE426408T1 (de) | 2009-04-15 |
KR20050094817A (ko) | 2005-09-28 |
CR9813A (es) | 2008-07-29 |
EP1594523B1 (en) | 2009-03-25 |
CA2510058A1 (en) | 2004-07-22 |
US20040151741A1 (en) | 2004-08-05 |
EP1594523A2 (en) | 2005-11-16 |
CA2510058C (en) | 2010-03-16 |
CN1729011A (zh) | 2006-02-01 |
CN100525831C (zh) | 2009-08-12 |
WO2004060384A2 (en) | 2004-07-22 |
US8241640B2 (en) | 2012-08-14 |
BR0316871A (pt) | 2005-10-18 |
US7491403B2 (en) | 2009-02-17 |
NZ540425A (en) | 2009-03-31 |
ZA200504982B (en) | 2007-05-30 |
MXPA05006690A (es) | 2006-02-17 |
JP2006519761A (ja) | 2006-08-31 |
US20110293663A1 (en) | 2011-12-01 |
AU2003300666A1 (en) | 2004-07-29 |
WO2004060384A3 (en) | 2004-10-07 |
DE60326887D1 (de) | 2009-05-07 |
IL168745A0 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053424D0 (no) | Forbedrede farmasoytiske botulinumtoksin-preparater. | |
AU2019201902B8 (en) | Dermal delivery | |
US20120321579A1 (en) | Surfactant compositions | |
JP6131194B2 (ja) | 皮膚科学的症状を処置するためのエンプティナノ粒子組成物およびその使用 | |
MY124853A (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives. | |
HUP0303976A2 (hu) | Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával | |
ATE314067T1 (de) | Cannabinol-11-säurederivate als entzündungshemmer und analgetika | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
JP2020511548A (ja) | 治療用のボツリヌス神経毒素 | |
KR20200040719A (ko) | 효능 지속시간이 연장된 보툴리눔 독소 조성물 | |
DK1343472T3 (da) | Thixotropisk næsespray | |
IL146132A0 (en) | Preparations for the application of anti-infective and/or anti-inflammatory agents to external or internal parts of the human or animal body in functional and cosmetic tissue remodelling and repair treatments | |
ATE409495T1 (de) | Polynukleotide-bindende komplexe die sterolen und saponine enthalten | |
MX2013001099A (es) | Crema o gel de aplicación tópica con neurotoxina botulinica encapsulada en nanoparticulas liposomales para el tratamiento de la hiperhidrosis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |